Jerel Davis, Ph.D., is a Managing Director based in Vancouver, Canada. Since joining Versant in 2011, he has been involved in launching and investing in a number of Versant’s portfolio companies including Quanticel (sale), Novira (sale), Crispr (2016 IPO), Inception 4 (sale), Inception 5 (sale), Northern, Turnstone, BlueRock, Repare, VenatoRx and Akero. He has led Versant’s execution of creative corporate transactions with multiple pharmaceutical partners including Celgene, Roche and Bayer, and was instrumental in establishing Versant’s presence in Canada, including the creation of our company-building infrastructure in Vancouver, Toronto and Montreal. Jerel was promoted to Managing Director at Versant in 2015.
Prior to joining Versant, Jerel was Associate Principal at McKinsey and Company where he advised healthcare corporations in pharmaceuticals, biotechnology, medical device and molecular diagnostics. He has worked in a number of healthcare markets globally including the U.S., Europe, China, Russia and India. Jerel earned his doctorate from Stanford University, where he also completed his post-doctoral research.
What is Jerel Davis' net worth?
The estimated net worth of Jerel Davis is at least $17.92 million as of April 17th, 2023. Dr. Davis owns 443,713 shares of Chinook Therapeutics stock worth more than $17,921,568 as of April 19th. This net worth approximation does not reflect any other assets that Dr. Davis may own. Learn More about Jerel Davis' net worth.
How do I contact Jerel Davis?
Has Jerel Davis been buying or selling shares of Chinook Therapeutics?
Jerel Davis has not been actively trading shares of Chinook Therapeutics during the last ninety days. Most recently, Davis Jerel sold 295,808 shares of the business's stock in a transaction on Monday, April 17th. The shares were sold at an average price of $20.75, for a transaction totalling $6,138,016.00. Following the completion of the sale, the director now directly owns 443,713 shares of the company's stock, valued at $9,207,044.75. Learn More on Jerel Davis' trading history.
Who are Chinook Therapeutics' active insiders?
Are insiders buying or selling shares of Chinook Therapeutics?
In the last twelve months, insiders at the sold shares 3 times. They sold a total of 26,123 shares worth more than $586,102.54. The most recent insider tranaction occured on August, 1st when insider Andrew James King sold 1,168 shares worth more than $45,587.04. Insiders at Chinook Therapeutics own 16.8% of the company.
Learn More about insider trades at Chinook Therapeutics. Information on this page was last updated on 8/1/2023.
